Immuneering Corporation
IMRX
$1.27
$0.021.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.08M | 16.77M | 16.62M | 16.41M | 16.76M |
| Depreciation & Amortization | 29.20K | 29.20K | 29.20K | 29.20K | 29.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.07M | 61.82M | 60.47M | 59.06M | 58.41M |
| Operating Income | -64.07M | -61.82M | -60.47M | -59.06M | -58.41M |
| Income Before Tax | -61.04M | -58.07M | -56.07M | -54.18M | -53.47M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.04 | -58.07 | -56.07 | -54.18 | -53.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.04M | -58.07M | -56.07M | -54.18M | -53.47M |
| EBIT | -64.07M | -61.82M | -60.47M | -59.06M | -58.41M |
| EBITDA | -63.69M | -61.43M | -60.09M | -58.69M | -58.06M |
| EPS Basic | -2.03 | -1.97 | -1.91 | -1.86 | -1.89 |
| Normalized Basic EPS | -1.28 | -1.24 | -1.21 | -1.18 | -1.19 |
| EPS Diluted | -2.03 | -1.97 | -1.91 | -1.86 | -1.89 |
| Normalized Diluted EPS | -1.28 | -1.24 | -1.21 | -1.18 | -1.19 |
| Average Basic Shares Outstanding | 119.92M | 118.14M | 117.56M | 116.55M | 113.63M |
| Average Diluted Shares Outstanding | 119.92M | 118.14M | 117.56M | 116.55M | 113.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |